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Introduction. In recent years new adjuvant radiation schedules in breast cancer have been incorporated to our daily practice
with a tendency to hypofractionation or simultaneous integrated boost (SIB). Toxicity is frequently a concern when using these
schemes.
Purpose. To compare dosimetry parameters of sequential versus SIB in breast adjuvant radiotherapy with 3D conventional
radiotherapy. To identify factors related to toxicity.
Material and methods. In 2011, 213 patients were treated with different schemes of adjuvant radiotherapy in breast cancer. We
retrospectively analyse the relationship of acute toxicity with different variables: PTVvolume, PTVboost-volumen, Radiation
scheme, Total Dose, age, breast right/left, quadrant, grade, time of year, previous chemotherapy and hormone-therapy. ANOVA
analysis for quantitative variables and Kruskal–Wallis for qualitative variables. Retrospective dosimetry comparison of 63 cases of
sequential boost (25–35 fractions, 2Gy/fraction) versus 57 cases of SIB (2.30, 2.47 or 2.58Gy/fraction) Dose equivalence calculated
according to the Linear Quadratic Model considering an alpha/beta of 4.6Gy.
Results. Skin acute toxicity G0 23.9%, G1 46.9%, G2 24.4%, G3 4.7%. No cardiac acute toxicity was reported and only 3 patients
presented G1 pulmonary acute toxicity (not included in the statistical analysis). We found statistical differences with PTV volume
(p=0.000) and sequential boost scheme (p=0.005) related to acute skin toxicity. Dosimetry comparison with T-student analysis
did not ﬁnd statistical signiﬁcance between the mean differences.
Conclusions. The mean differences of the dosimetry parameters analyzed were not signiﬁcant with a conﬁdence interval of 95%.
We found statistically signiﬁcant differences of acute skin toxicity in relation to PTV volume and sequential boost.
http://dx.doi.org/10.1016/j.rpor.2013.03.855
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Purpose. The aim of this study was to demonstrate feasibility and analyse dosimetric differences in prone and supine position
breast cancer radiotherapy in women with large or pendulous breast.
Methods. Ten post-lumpectomy breast cancer patients underwent supine and prone CT-based treatment plan. On each data-set,
the whole breast, the ipsilateral lung and the heart were outlined. Multisegment tangential-ﬁelds plans were generated for each
position. Target coverage, homogeneity, overdosage outside breast and organ at risk sparing were analyzed and compared for
supine and prone position.
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Results. Coverage and dose homogeneity of the PTV measured by D90 and V95% were similar for both plans although breast
maximum dose was higher in the supine plan (p=0.017). Prone position reduced the percentage of ipsilateral lung receiving
20Gy (V20Gy) from 26.5% to 2.9% (p=0.007), medium lung dose, as well as the percentage of the heart receiving 35Gy heart
(V35Gy) from 3.4% to 1.2% (p=0.038). Overdosage of areas outside breast PTV were also consistently reduced with prone position
(p=0.012). Additionally, average number of segments and monitor units needed were reduced in prone position.
Conclusions. Prone position in large breast women appears to favour normal tissue sparing in breast radiotherapy as compared
to supine position, without diminishing the target coverage.
http://dx.doi.org/10.1016/j.rpor.2013.03.856
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Hypothesis. SBRT with Novalis Exactrac Adaptive Gating Linac (Brainlab®) is a secure, highly accurate and feasible PBI technique
with intrafraction control of breast movement.
Goals. 1. Asses the feasibility of applying SBRTwithGating in patientswith breast cancer of VGPwith and accelerated fractionation
(5 fractions×6Gy) in alternate days. 2. Reduce the PTV margin due to the possibility to quantify the breast movement during the
respiratory cycle (RC) and to irradiate in a selected phase of that cycle. 3. Identify and quantify acute and late toxicity according
to RTOG and CTCAE scales.
Inclusion criteria. Women age ≥60 years, pT1 (<2 cm) after breast conserving surgery, surgical margins ≥2mm, pathological
conﬁrmation of inﬁltrating ductal carcinoma, pN0, ECOG 0-1, luminal subtype.
Methods. •Placement of ﬁducial markers close to the surgical bed, prior to simulation. •CT simulation in supine position with
immobilization device and infrared spheres on the skin, as external ﬁducials. •3D conformal radiation therapy with iPlan Net®
(DVH assessed and approved according to ASTRO recommendations for PBI constraints). •Intrafraction control of PTV motion
with Novalis Exactrac Gating System (quantiﬁcation of breast movement during the RC by the correlation of the internal marker
and the external ﬁducials). •PTV irradiation in the selected gated area of the RC. •Assessed of clinical and toxicity outcomes.
http://dx.doi.org/10.1016/j.rpor.2013.03.857
